Death associated proteins, and THAP1 and PAR4 pathways in apoptosis control

• US 7,572,886 B2
• Filed: 12/10/2002
• Issued: 08/11/2009
• Est. Priority Date: 12/18/2001
• Status: Expired due to Fees

• Current Assignee: Centre National De La Recherche Scientifique, Endocube S.A.S.
• Original Assignee: Centre National De La Recherche Scientifique
• Inventors: Roussigne, Myriam, Amalric, Francois, Girard, Jean-Philippe, Clouaire, Thomas
• Primary Examiner(s): Helms; Larry R.
• Assistant Examiner(s): Yao; Lei
• Application Number:
  US10/317,832
• Publication Number:
  US 20030186337A1
• Time in Patent Office: 2,436 Days
• Field of Search: None
• US Class Current: 530/350
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 15/12 for climacteric disorders
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/4747 : Apoptosis related proteins
• CPC Class Codes: C07K 2319/30 : Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.

Claims

1. An isolated or purified fragment of SEQ ID NO:

3 comprising the amino acid sequence 143-213 of SEQ ID NO;

3.

5. The isolated or purified fragment of claim 1, wherein said amino acid sequence consists of the amino acid sequence 143-213 of SEQ ID NO:

3.

2. A fusion protein comprising an Fc region of an immunoglobulin fused to a fragment of SEQ ID NO:

3, said fragment comprising the amino acid sequence 143-213 of SEQ ID NO;

3.

6. The fusion protein of claim 2, wherein said fragment of SEQ ID NO:

3 consists of the amino acid sequence 143-213 of SEQ ID NO;

3.

3. An oligomeric protein comprising a plurality of fragments of SEQ ID NO:

3, said fragments comprising the amino acid sequence 143-213 of SEQ ID NO;

3.

7. The oligomeric protein of claim 3, wherein at least one of said plurality of fragments of SEQ ID NO:

3 consists of the amino acid sequence 143-213 of SEQ ID NO;

3.

4. A medicament comprising a fragment of SEQ ID NO:

3 comprising the amino acid sequence 143-213 of SEQ ID NO;

3, together with a pharmaceutically acceptable carrier.

8. The medicament of claim 4, wherein said fragment of SEQ ID NO:

3 consists of the amino acid sequence 143-213 of SEQ ID NO;

3.